As a novel therapeutic module, the dendritic cell (DC) based cancer vaccine has been recognized with great hope in eliminating cancers, including minimal residual cells, without harming normal tissue. A key factor in initiating and operating the immune system against foreign bodies including tumor cells, the DC has been regarded as the next possible breakthrough in new cancer therapy. However, the results of more than 15 years of clinical studies with DC vaccine revealed the difficulties fulfilling this expectation. Evidence has disclosed that the DC activation required for proper tumor-specific effector CD4 + and CD8 + T cell stimulation is inhibited in the micro-environment of cancer. Studies have further reported that DC phenotypes in cancer tissue and draining lymph nodes are mostly immature, which results in regulatory immune responses. Also, the existence of myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) adversely affect both DC function and immune suppression in the cancer-environment. In this review, the impact of an inflammatory micro-environment induced by cancer on the effect of DC-based cancer immunotherapy and the possibility of a clinical efficacy improvement are discussed.
Introduction
The role of DC is at the center of the immune system by initiating, progressing and regulating the responses against pathogens including tumors. After the first successful clinical achievement in DC-based immunotherapy trials in follicular lymphoma and melanoma in the mid-1990s, 1, 2 the DC vaccine has been successfully used to treat patients with melanoma, lymphoma and renal cell carcinoma. [3] [4] [5] [6] [7] However clinical expectations have not been fulfilled due to an overall clinical response rates of under 10∼15%, the usual response rates observed in various types of immunotherapies. [6] [7] [8] [9] [10] [11] Although the clinical expectation has not been satisfied, the outcomes of many clinical trials with tumor antigen-loaded conventional DCs have provided proof that therapeutic immunity can be elicited. [12] [13] [14] The clinical data has helped to establish a standard for properly 
Inflammatory nature of tumor micro-environment
The development of about 15∼20% of malignancies worldwide are known to be related to chronic inflammation, including esophageal, gastric, hepatic, pancreatic, and colorectal cancer. 51 Inflammatory mediators produced by the cancer cell can create an inflammatory micro-environment and cause both leukocyte recruitment and angiogenesis. 
MDSCs in the tumor micro-environment
The mechanisms by which chronic inflammation promotes the onset and development of tumors are classified into non-immunological and immunological ways. 56 The nonimmune mechanisms include 1) the production of reactive oxygen species which cause DNA mutation, 2) the production of pro-angiogenic factors, like VEGF which promote tumor neo-vascularization, 3) the production of matrix metalloproteases which facilitate invasion and metastasis. [57] [58] [59] The predominant immune mechanism is the disturbance of myelopoiesis and hemopoiesis, which causes a deficiency in APCs and in dysfunctional cell-mediated antitumor immunity. A key molecule in this deficiency is MDSC. 25 In individuals with an established cancer, MDSCs are a major factor in preventing the efficacy of cancer vaccines that require an immune-competent host. 60 function, including OX40. 13 Another therapeutic vaccination protocol can combine improved DC vaccine with chemotherapy to exploit immunogenic chemotherapy regimens. 82 Conclusively, correcting the immunological balance in the cancer micro-environment from suppression to a tumor-rejecting condition may be the key factor in succeeding with a DC vaccine clinical trial.
